Table.2 The protective efficacy of various types of sporozoite-based malaria vaccines against homologous and heterologous sporozoite—induced malaria infections

NF54 -CPS

NF54-infected mosquitoes

PfNF54

100(10/10)

[20]

NF54 -CPS

NF54-infected mosquitoes

Pf3D7

100 (5/5)

[21]

NF54 -CPS

NF54-infected mosquitoes

NF54, NF166.C8, NF135.C10

100(5/5)-for NF54

20(2/10)-forNF135.C10

11(1/9)- for NF166.C8

[22]

NF54 -CPS

NF54-infected mosquitoes

NF135.C10

15(2/13)

[25]

NF54 -CPS

NF54-infected mosquitoes

PfNF54

70(7/10)

[23]

NF54 -CPS

NF54-infected mosquitoes

PfNF54

66(4/6)

[24]

NF54-irradiated

NF54-infected mosquitoes

NF54, Pf3D7, Pf7G8

92(24/26)

[18]

NF54-irradiated

Infected mosquito

PfNF54, 3D7

33(1/3)

[33]

X-irradiated Pv-SPZ

Infected mosquito

Pv

42(5/12)

[19]

RTS, S /AS01B,

RTS,S/AS02A

IM injection

Pf3D7

32–50

[32]

RTS,S

IM injection

Pf3D7

41(9/22)

[34]

RTS,S

IM injection

Pf3D7

29(2/7)

[35]

RTS,S/SBAS2

IM injection

Pf3D7

43(18/41)

[36]

RTS,S/AS02A

IM injection

Pf3D7

42(8/19)

[31]

Ad35.CS.01- RTS,S/AS01

IM injection

Pf3D7

44 and 52

[37]

RTS,S/AS02A and MVA-CS

IM/ID injection

Pf3D7

33(4/12)

[38]

RTS,S

IM injection

Pf7G8

14(2/14)

[39]

RTS,S/AS01B with ME-TRAP

IM injection

Pf3D7

82(14/17) & 75(12/16)

[40]

RTS,S/AS01

IM injection

Pf3D7

63(10/16) & 87(26/30)

[41]

R32N51-81

IM injection

Pf3D7

36(4/11)

[42]

ChAd63-MVA CS, & ChAd63-MVA ME-TRAP

IM injection

Pf3D7

7(1/15) &13(2/15)

[43]

PfSPZ vaccine

IV injection

PfNF54, 3D7

66(6/9) &100(6/6)

[28]

PfSPZ vaccine

IV injection

NF54, NF166.C8, NF135.C10

92(12/13)-homologous

80(4/5)-heterologous

[29]

PfSPZ challenge

DVI

PfSPZchallenge injection by DVI

33(3/9), 100(9/9)

[26]

PfSPZ vaccine

IM injection

PfSPZ challenge injection by DVI

20(4/20) & 100(4/4)

[27]